664 related articles for article (PubMed ID: 32024476)
1. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
[TBL] [Abstract][Full Text] [Related]
2. Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
Rassner M; Waldeck S; Follo M; Jilg S; Philipp U; Jolic M; Wehrle J; Jost PJ; Peschel C; Illert AL; Duyster J; Scherer F; von Bubnoff N
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982486
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
[TBL] [Abstract][Full Text] [Related]
5. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
6. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N
Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.
Namløs HM; Boye K; Mishkin SJ; Barøy T; Lorenz S; Bjerkehagen B; Stratford EW; Munthe E; Kudlow BA; Myklebost O; Meza-Zepeda LA
Mol Cancer Ther; 2018 Nov; 17(11):2473-2480. PubMed ID: 30097488
[TBL] [Abstract][Full Text] [Related]
8. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncology; 2016; 90(2):112-7. PubMed ID: 26779618
[TBL] [Abstract][Full Text] [Related]
9. Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time?
Gómez-Peregrina D; García-Valverde A; Pilco-Janeta D; Serrano C
Curr Treat Options Oncol; 2021 Feb; 22(4):32. PubMed ID: 33641024
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.
Boonstra PA; Ter Elst A; Tibbesma M; Gietema JA; Schuuring E; Reyners AKL
Oncologist; 2019 Jun; 24(6):e387-e390. PubMed ID: 30670599
[TBL] [Abstract][Full Text] [Related]
12. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
[TBL] [Abstract][Full Text] [Related]
13. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
14. Pre-and Postoperative Circulating Tumour DNA in Patients With Gastrointestinal Stromal Tumour - A Methodological Assessment Study.
Brinch CM; Aggerholm-Pedersen N; Poulsen TS; Skovrider-Ruminski W; DE Heer P; Penninga L; Krarup-Hansen A; Hogdall E
Anticancer Res; 2022 Nov; 42(11):5527-5537. PubMed ID: 36288871
[TBL] [Abstract][Full Text] [Related]
15. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Zhou Y; Zhang X; Wu X; Zhou Y; Zhang B; Liu X; Wu X; Li Y; Shen L; Li J
Cancer Med; 2020 Sep; 9(17):6225-6233. PubMed ID: 32677196
[TBL] [Abstract][Full Text] [Related]
16. Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST.
Xu H; Chen L; Shao Y; Zhu D; Zhi X; Zhang Q; Li F; Xu J; Liu X; Xu Z
Mol Cancer Ther; 2018 Jan; 17(1):290-296. PubMed ID: 29133619
[TBL] [Abstract][Full Text] [Related]
17. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA.
Maier J; Lange T; Kerle I; Specht K; Bruegel M; Wickenhauser C; Jost P; Niederwieser D; Peschel C; Duyster J; von Bubnoff N
Clin Cancer Res; 2013 Sep; 19(17):4854-67. PubMed ID: 23833305
[TBL] [Abstract][Full Text] [Related]
18. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
20. An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.
Gheysen M; Vander Borght S; Lehnert S; Vanslembrouck R; Vanden Bempt I; Schöffski P
Oncol Res Treat; 2020; 43(9):470-473. PubMed ID: 32640452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
